MARLBOROUGH, Mass.,
Nov. 12, 2019 /PRNewswire/
-- Boston Scientific Corporation (NYSE: BSX) (the "Company")
completed a public offering of €900.0 million aggregate principal
amount of 0.625% Senior Notes due 2027 (the "Notes"). The
Company has applied to list the Notes on the New York Stock
Exchange.
In addition, the Company completed its previously announced cash
tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount of
certain outstanding senior notes, pursuant to which it accepted
$206,429,000, $566,455,000, and $227,117,000 of tendered principal amounts of its
4.125% Senior Notes due 2023, 4.000% Senior Notes due 2028 and
3.850% Senior Notes due 2025, respectively on the early settlement
date.
The Company used the net proceeds from the offering to (i) fund
the Tender Offer and (ii) pay accrued and unpaid interest,
premiums, fees and expenses in connection with the Tender Offer.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for 40 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements may be
identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words.
These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the
time and are not intended to be guarantees of future events or
performance. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A – Risk
Factors in Quarterly Reports on Form 10-Q we have filed or
will file hereafter. We disclaim any intention or obligation
to publicly update or revise any forward-looking statements to
reflect any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this press release.
CONTACT:
|
|
Media:
|
Kate
Haranis
|
|
Investors:
|
Susie Lisa,
CFA
|
|
508-683-6585
(office)
|
|
|
508-683-5565
(office)
|
|
Media
Relations
|
|
|
Investor
Relations
|
|
Boston Scientific
Corporation
|
|
|
Boston Scientific
Corporation
|
|
kate.haranis@bsci.com
|
|
|
BSXInvestorRelations@bsci.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/boston-scientific-completes-900-million-offering-of-senior-notes-and-1-0-billion-tender-offer-300956841.html
SOURCE Boston Scientific Corporation